excretion, because about 50% to 80% of hepatic bile is stored in the gall bladder during fasting.3`5 Attempts to abolish gall bladder storage function by using a continuous intraduodenal infusion of nutrients"' has been recently shown by Everson et all' to be ineffective because of failure to maintain the gall bladder tonically contracted.
A method combining cholescintigraphy with nasoduodenal intubation has recently been developed for measurement of gall bladder storage function in healthy subjects" and has been applied to measurement of biliary lipid mass stored in the fasting gall bladder. It is of potential value for measuring the mass of drug in the gall bladder.
The aim of this study was (Fig. 1) On the day before the study, the subjects were admitted to a clinical investigation ward. On the following morning, a double lumen nasoduodenal tube (Anpro-20, Andersen, USA) was advanced under fluoroscopic control in the fasting state to position the proximal outlet (duodenal perfusion tube, id 1 mm) opposite the ampulla of Vater. The distal tube (aspiration tube, id 2-5 mm) was positioned at the ligament of Treitz, allowing 20 cm mixing segment. This distal tube was radiopaque, and radiopaque marks were also attached at the distal end of the perfusion tube to assist correct fluoroscopic positioning.
Two and a half grams per litre polyethylene glycol solution (PEG, mw 4000) was prepared in normal saline and continuously perfused into the duodenum (Fig. 1 ) at the rate of 5 ml/min by a peristalstic pump (model 502S, Watson Marlow, UK). After allowing 60 minutes to achieve a steady state, 1 g Cefotetan (ICI, UK) was injected as a single iv bolus, and duodenal aspirate was obtained by syphonage at 30 minute intervals for four hours and at hourly intervals thereafter for a total seven hours. As part of a validation study, two of the seven subjects were studied during continuous iv infusion of ICG. The ICG solution (Indocyanine green, HW&D, USA) was prepared in normal saline containing 5% human albumin immediately before the study. Intravenous infusion started three hours before Cefotetan administration ( Fig. 1) , to allow equilibration of hepatic output with its iv input,3' 3 and continued until the end of the study at a constant rate of 0*2 mg/kg/h (model 975, Harvard Infusion Pump, USA). The ICG solution was kept in the dark during preparation and iv administration. Two millicuries 'Tc HIDA (1Tc sodium n-[n(2,6-diethylphenlyl-carbamylmethyl)] iminodiacetate, Amersham, UK) was injected as an iv bolus in five subjects 90 minutes before the end of the duodenal perfusion of polyethylene glycol. Two hours later, anterior and posterior abdominal gamma camera counting (one minute interval) was carried out with a gamma camera/computer system (model KR7, SELO, Italy). Data were stored in the computer and later reanalysed using an area of interest facility to outline the gall bladder area. Interference for liver background activity was corrected by subtracting from gall bladder counts the activity detected in an equivalent area of the liver adjacent to the gall bladder. Differences in gall bladder depth from the gamma camera crystal were compensated for by using the formula:" GB counts= (anterior GB counts2+posterior GB counts2)'c (where GB=gall bladder).
After gall bladder gamma camera scanning, gall bladder volume was measured by real time ultrasonography (model MK 300C, sector probe 3 0 MHz, ATL, USA) as described by Everson et Giall bladder mass of Cefotetan was calculated according to the following formula:
(ii) Cm in GB= Cm (1 ml GB bile)x 'Tc HIDA activity over the Gb area 'Tc HIDA activity (1 ml GB bile)
where m=mass and GB=gall bladder Total biliary excretion of Cefotetan was calculated according to the following formula: Cefotetan/bile acid and Cefotetan/ICG ratios were calculated from duodenal outputs (i). Absolute values for both measurements were expressed as a percent of the peak values, which were considered to be 100%. Results were expressed as median values. Regression lines were calculated using the least square method. The linearity was tested by fitting a power curve to log transformed variables, a power less than 1 indicating a curvilinear relationship.
Results
VALIDATION STUDIES (Fig. 2 ) Cefotetan/bile acid ratio and Cefotetan/ICG ratio declined with time in both subjects studied during ICG intravenous infusion. A single regression line was derived for the combined data from the two measurements in both subjects, and the data from both individual measurements were equally distributed around this regression line.
GALL BLADDER MASS AND CONCENTRATION
(Table, Fig. 3 ) The mass of Cefotetan stored in the gall bladder in the five subjects studied ranged from 17.9 to 111*9 mg (45.2 mg median value). Gall bladder volume in individual subjects ranged from 10-6 to 21-1 ml (16-4 ml median value). Cefotetan concentration in the gall bladder ranged from 1*4 to 7*1 mg/ml (2-8 mg/ml median value).
BILIARY EXCRETION (Table, Fig. 3) Cumulative duodenal excretion of Cefotetan in the seven subjects studied ranged from 18-4 to 151-9 mg (51-1 mg median value) during the seven hours study. Total biliary excretion (duodenal excretion plus gall bladder mass) ranged in individual subjects from 47.2 to 263-8 mg (108-6 median value).
T.,2 IN BILE (Figs 4 and 5)
The profile of Cefotetan duodenal excretion in Table Individual individual subjects is shown in Fig
Cefotetan duodenal excretion fluctu whole study period in all subjects, ar relationship between Cefotetan duo and time (r=0-11, NS). By contras decline of Cefotetan/bile acid ratiu pooled data from all subjects. This r better described by a curve (y r=0-315, p<0-05) than by a straig Cefotetan in bile calculated on t relationship was 100 minutes.
Discussion
Our validation study has shown thal philic substance in bile can be m Figure 4 with Figure 5 . Duodenal excretion of the antibiotic fluctuated during the whole study in all subjects (Fig. 4) 
